207 related articles for article (PubMed ID: 30251424)
1. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Chaignot C; Zureik M; Rey G; Dray-Spira R; Coste J; Weill A
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1239-1248. PubMed ID: 30251424
[TBL] [Abstract][Full Text] [Related]
2. Baclofen for alcohol use disorder.
Agabio R; Saulle R; Rösner S; Minozzi S
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
[TBL] [Abstract][Full Text] [Related]
3. Alcohol addiction - the safety of available approved treatment options.
Antonelli M; Ferrulli A; Sestito L; Vassallo GA; Tarli C; Mosoni C; Rando MM; Mirijello A; Gasbarrini A; Addolorato G
Expert Opin Drug Saf; 2018 Feb; 17(2):169-177. PubMed ID: 29120249
[TBL] [Abstract][Full Text] [Related]
4. Baclofen for alcohol use disorder.
Minozzi S; Saulle R; Rösner S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.
Heikkinen M; Taipale H; Tanskanen A; Mittendorfer-Rutz E; Lähteenvuo M; Tiihonen J
Addiction; 2021 Aug; 116(8):1990-1998. PubMed ID: 33394527
[TBL] [Abstract][Full Text] [Related]
6. Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.
Fairbanks J; Umbreit A; Kolla BP; Karpyak VM; Schneekloth TD; Loukianova LL; Sinha S
Mayo Clin Proc; 2020 Sep; 95(9):1964-1977. PubMed ID: 32446635
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of alcoholism - an update on approved and off-label medications.
Soyka M; Müller CA
Expert Opin Pharmacother; 2017 Aug; 18(12):1187-1199. PubMed ID: 28658981
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Sinclair JM; Chambers SE; Shiles CJ; Baldwin DS
Drug Saf; 2016 Jul; 39(7):627-45. PubMed ID: 27023898
[TBL] [Abstract][Full Text] [Related]
10. Comparison of healthcare utilization among patients treated with alcoholism medications.
Mark TL; Montejano LB; Kranzler HR; Chalk M; Gastfriend DR
Am J Manag Care; 2010; 16(12):879-88. PubMed ID: 21348558
[TBL] [Abstract][Full Text] [Related]
11. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation.
Rolland B; Labreuche J; Duhamel A; Deheul S; Gautier S; Auffret M; Pignon B; Valin T; Bordet R; Cottencin O
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1631-6. PubMed ID: 26095229
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
Bahji A; Bach P; Danilewitz M; Crockford D; Devoe DJ; El-Guebaly N; Saitz R
J Addict Med; 2022 Nov-Dec 01; 16(6):630-638. PubMed ID: 35653782
[TBL] [Abstract][Full Text] [Related]
13. The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study.
Pignon B; Labreuche J; Auffret M; Gautier S; Deheul S; Simioni N; Cottencin O; Bordet R; Duhamel A; Rolland B
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28517239
[TBL] [Abstract][Full Text] [Related]
14. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
Rolland B; Auffret M; Labreuche J; Lapeyre-Mestre M; Dib M; Kemkem A; Grit I; Drelon M; Duhamel A; Cabe N; Vabret F; Guillin O; Baguet A; Masquelier C; Dervaux A; Deheul S; Bordet R; Carton L; Cottencin O; Jardri R; Gautier S
Expert Opin Drug Saf; 2017 Feb; 16(2):125-132. PubMed ID: 27984918
[TBL] [Abstract][Full Text] [Related]
15. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.
Leggio L; Falk DE; Ryan ML; Fertig J; Litten RZ
Handb Exp Pharmacol; 2020; 258():443-462. PubMed ID: 31628604
[TBL] [Abstract][Full Text] [Related]
16. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
Rolland B; Valin T; Langlois C; Auffret M; Gautier S; Deheul S; Danel T; Bordet R; Cottencin O
Int Clin Psychopharmacol; 2015 Jan; 30(1):49-53. PubMed ID: 25356633
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapies for the Treatment of Alcohol Use Disorders During Pregnancy: Time to Reconsider?
Kelty E; Terplan M; Greenland M; Preen D
Drugs; 2021 May; 81(7):739-748. PubMed ID: 33830479
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment of alcohol use disorder. Scientific evidence.
Attilia F; Perciballi R; Rotondo C; Capriglione I; Iannuzzi S; Attilia ML; Vitali M; Alessandrini G; Scamporrino MCM; Fiore M; Ceccanti M;
Riv Psichiatr; 2018; 53(3):123-127. PubMed ID: 29912214
[TBL] [Abstract][Full Text] [Related]
19. Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Castrén S; Mäkelä N; Alho H
Curr Opin Psychiatry; 2019 Jul; 32(4):266-274. PubMed ID: 30973369
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?
Antonelli M; Sestito L; Tarli C; Addolorato G
Eur J Intern Med; 2022 Sep; 103():13-22. PubMed ID: 35597734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
